SION
Sionna Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.66 EPS
Last earnings +1.8% on 2026-05-12
$42.18
▼ -1.38%$42.18▲ +166.29%
over 1Y
L $14.83EODHDH $45.24
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.4%
1W-1.4%
1M-2.9%
3M+16.6%
YTD+7.6%
1Y+166.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Conservative balance sheet (liabilities/equity 0.06x).
Return on equity -24.5% · latest
Sionna Therapeutics, Inc. shows limited reported revenue, and -24.5% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$70.6M | -$89.0M |
| Net income | -$61.7M | -$75.3M |
| Diluted EPS | -$15.99 | -$1.88 |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.84B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-4.0%
FCF yield-3.5%
Quality & risk
ROIC (est.)-22.9%
Free cash flow-$66.7M
Total debt—
Net cash$58.5M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-172026-06-18open ↗144/AFiling2026-06-01open ↗4Period ending 2026-05-272026-05-29open ↗
Frequently asked
- Is Sionna Therapeutics, Inc. (SION) a buy?
- SION currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.06x).
- What is Sionna Therapeutics, Inc.'s quality score?
- SION scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002036042, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:43:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.